|
[Epidermal growth factor (Heberprot-P®) in chronic ulcers] |
Klappenbach R, Alcaraz A, Pichon-Riviere A, Augustovski F, García Martí S, Bardach A, Ciapponi A, López A, Rey-Ares L |
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Klappenbach R, Alcaraz A, Pichon-Riviere A, Augustovski F, García Martí S, Bardach A, Ciapponi A, López A, Rey-Ares L. [Epidermal growth factor (Heberprot-P®) in chronic ulcers] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Documentos de Evaluación de Tecnologías Sanitarias, Informe de Respuesta Rapida No 520. 2017 Authors' conclusions Evidence of low quality shows that intralesional injections of epidermal growth factor in chronic diabetic foot ulcers do not reduce the number of amputations although it may show a higher rate of ulcer healing. The evidence comes from placebo-controlled studies, not compared with other therapeutic treatments.
There is no evidence assessing the use of epidermal growth factor in other chronic ulcers of different etiologies.
Most clinical practice guidelines do not recommend using growth factor to treat chronic ulcers. This technology is commercially available mainly in Latin American and Asian countries and only some health systems in these countries cover it. Final publication URL www.iecs.org.ar Indexing Status Subject indexing assigned by CRD MeSH Epidermal Growth Factor; Humans; Skin Diseases; Stomach Ulcer; Ulcer Language Published Spanish Country of organisation Argentina English summary There is no English language summary available. Address for correspondence Institute for Clinical Effectiveness and Health Policy, Viamonte 2146 - 3 Piso, C1056ABH Ciudad de Buenos Aires, Argentina Tel: +54 11 49 66 00 82 Fax:+54 11 49 53 40 58 Email: info@iecs.org.ar AccessionNumber 32017000285 Date abstract record published 13/06/2017 |
|
|
|